Characteristics of patients with high or low baseline bleeding scores
| . | Development cohort . | . | Validation cohort . | . | ||
|---|---|---|---|---|---|---|
| . | Low (n = 297), n (%) . | High (n = 42), n (%) . | P value . | Low (n = 119), n (%) . | High (n = 24), n (%) . | P value . |
| Age, years; median (range) | 62 (19-76) | 59 (23-74) | .196 | 63 (20-85) | 67 (37-78) | .202 |
| Sex | .413 | .819 | ||||
| Male | 162 (55) | 20 (48) | 74 (62) | 14 (58) | ||
| Female | 135 (45) | 22 (52) | 45 (38) | 10 (42) | ||
| ELN2017 cytogenetic risk group | .735 | .999 | ||||
| Favorable | 34 (12) | 6 (14) | 11 (9) | 2 (8) | ||
| Intermediate | 204 (70) | 27 (64) | 65 (56) | 14 (58) | ||
| Adverse | 55 (19) | 9 (21) | 40 (34) | 8 (33) | ||
| Somatic mutations, presence | ||||||
| NPM1 | 81 (27) | 9 (21) | .463 | 19 (16) | 6 (25) | .375 |
| DNMT3A | 64 (22) | 9 (21) | .999 | 21 (18) | 2 (8) | .367 |
| NRAS | 50 (17) | 11 (26) | .139 | 18 (15) | 6 (25) | .241 |
| RUNX1 | 49 (16) | 3 (7) | .167 | 26 (22) | 4 (17) | .784 |
| TET2 | 45 (15) | 8 (19) | .500 | 14 (12) | 6 (25) | .107 |
| ASXL1 | 41 (14) | 4 (10) | .627 | 22 (18) | 3 (13) | .768 |
| FLT3-ITD | 44 (15) | 7 (17) | .817 | 16 (13) | 4 (17) | .747 |
| IDH2 | 31 (10) | 7 (17) | .291 | 21 (18) | 1 (4) | .125 |
| SRSF2 | 32 (11) | 5 (12) | .793 | 22 (18) | 1 (4) | .125 |
| IDH1 | 37 (12) | 3 (7) | .445 | 12 (10) | 1 (4) | .696 |
| TP53 | 18 (6) | 5 (12) | .183 | 24 (20) | 2 (8) | .248 |
| FLT3-TKD | 29 (10) | 3 (7) | .781 | 13 (11) | 4 (17) | .488 |
| Complete blood count, median (IQR) | ||||||
| Hemoglobin, g/dL | 8.7 (8.1-9.4) | 8.3 (7.6-8.5) | <.001 | 8.7 (7.8-9.9) | 8.7 (8.2-10.1) | .713 |
| Platelets, ×109/L | 56 (32-98) | 29 (20-35) | <.001 | 65 (45-123) | 36 (26-55) | <.001 |
| WBC, ×109/L | 5.8 (2.3-19.0) | 18.3 (6.4-47.5) | <.001 | 6.6 (2.1-31.0) | 40.4 (15.8-73.0) | <.001 |
| Coagulation, median (IQR) | ||||||
| PT-INR | 1.2 (1.1-1.3) | 1.5 (1.4-1.6) | <.001 | 1.2 (1.1-1.3) | 1.6 (1.5-1.8) | <.001 |
| PTT, sec | 32.4 (29.7-36.5) | 41.6 (34.9-48.4) | <.001 | 30.7 (27.8-34.1) | 34.3 (30.5-43.4) | .005 |
| Fibrinogen, mg/dL | 374 (304-465) | 370 (257-460) | .429 | 430 (330-562) | 356 (146-547) | .031 |
| D-dimer, ng/mL FEU | 1526 (852->4000) | >4000 (2471->4000) | .010 | 1508 (724-3950) | 9420 (1670->20 000) | .004 |
| Chemistry median (IQR) | ||||||
| Creatinine, mg/dL | 0.81 (0.66-0.97) | 0.81 (0.69-1.00) | .656 | 0.90 (0.76-1.10) | 1.13 (0.96-1.49) | .001 |
| Albumin, g/dL | 3.6 (3.3-3.9) | 3.0 (2.6-3.5) | <.001 | 3.5 (3.1-4.0) | 3.2 (2.8-3.5) | .012 |
| Bilirubin, mg/dL | 0.4 (0.3-0.7) | 0.6 (0.4-0.9) | .002 | 0.6 (0.4-1.0) | 0.6 (0.5-1.2) | .763 |
| LDH, U/L | 312 (204-377) | 752 (457-1679) | <.001 | 833 (575-1359) | 2130 (1296-3603) | <.001 |
| ISTH-DIC score, median (IQR)* | 4 (3-4) | 6 (5-6) | <.001 | 3 (2-4) | 6 (5-7) | <.001 |
| Thrombosis | .002 | .052 | ||||
| None | 264 (89) | 30 (71) | 110 (92) | 19 (79) | ||
| Catheter-associated | 23 (8) | 6 (14) | 6 (5) | 2 (8) | ||
| Noncatheter-associated | 10 (3) | 6 (14) | 3 (3) | 3 (13) | ||
| . | Development cohort . | . | Validation cohort . | . | ||
|---|---|---|---|---|---|---|
| . | Low (n = 297), n (%) . | High (n = 42), n (%) . | P value . | Low (n = 119), n (%) . | High (n = 24), n (%) . | P value . |
| Age, years; median (range) | 62 (19-76) | 59 (23-74) | .196 | 63 (20-85) | 67 (37-78) | .202 |
| Sex | .413 | .819 | ||||
| Male | 162 (55) | 20 (48) | 74 (62) | 14 (58) | ||
| Female | 135 (45) | 22 (52) | 45 (38) | 10 (42) | ||
| ELN2017 cytogenetic risk group | .735 | .999 | ||||
| Favorable | 34 (12) | 6 (14) | 11 (9) | 2 (8) | ||
| Intermediate | 204 (70) | 27 (64) | 65 (56) | 14 (58) | ||
| Adverse | 55 (19) | 9 (21) | 40 (34) | 8 (33) | ||
| Somatic mutations, presence | ||||||
| NPM1 | 81 (27) | 9 (21) | .463 | 19 (16) | 6 (25) | .375 |
| DNMT3A | 64 (22) | 9 (21) | .999 | 21 (18) | 2 (8) | .367 |
| NRAS | 50 (17) | 11 (26) | .139 | 18 (15) | 6 (25) | .241 |
| RUNX1 | 49 (16) | 3 (7) | .167 | 26 (22) | 4 (17) | .784 |
| TET2 | 45 (15) | 8 (19) | .500 | 14 (12) | 6 (25) | .107 |
| ASXL1 | 41 (14) | 4 (10) | .627 | 22 (18) | 3 (13) | .768 |
| FLT3-ITD | 44 (15) | 7 (17) | .817 | 16 (13) | 4 (17) | .747 |
| IDH2 | 31 (10) | 7 (17) | .291 | 21 (18) | 1 (4) | .125 |
| SRSF2 | 32 (11) | 5 (12) | .793 | 22 (18) | 1 (4) | .125 |
| IDH1 | 37 (12) | 3 (7) | .445 | 12 (10) | 1 (4) | .696 |
| TP53 | 18 (6) | 5 (12) | .183 | 24 (20) | 2 (8) | .248 |
| FLT3-TKD | 29 (10) | 3 (7) | .781 | 13 (11) | 4 (17) | .488 |
| Complete blood count, median (IQR) | ||||||
| Hemoglobin, g/dL | 8.7 (8.1-9.4) | 8.3 (7.6-8.5) | <.001 | 8.7 (7.8-9.9) | 8.7 (8.2-10.1) | .713 |
| Platelets, ×109/L | 56 (32-98) | 29 (20-35) | <.001 | 65 (45-123) | 36 (26-55) | <.001 |
| WBC, ×109/L | 5.8 (2.3-19.0) | 18.3 (6.4-47.5) | <.001 | 6.6 (2.1-31.0) | 40.4 (15.8-73.0) | <.001 |
| Coagulation, median (IQR) | ||||||
| PT-INR | 1.2 (1.1-1.3) | 1.5 (1.4-1.6) | <.001 | 1.2 (1.1-1.3) | 1.6 (1.5-1.8) | <.001 |
| PTT, sec | 32.4 (29.7-36.5) | 41.6 (34.9-48.4) | <.001 | 30.7 (27.8-34.1) | 34.3 (30.5-43.4) | .005 |
| Fibrinogen, mg/dL | 374 (304-465) | 370 (257-460) | .429 | 430 (330-562) | 356 (146-547) | .031 |
| D-dimer, ng/mL FEU | 1526 (852->4000) | >4000 (2471->4000) | .010 | 1508 (724-3950) | 9420 (1670->20 000) | .004 |
| Chemistry median (IQR) | ||||||
| Creatinine, mg/dL | 0.81 (0.66-0.97) | 0.81 (0.69-1.00) | .656 | 0.90 (0.76-1.10) | 1.13 (0.96-1.49) | .001 |
| Albumin, g/dL | 3.6 (3.3-3.9) | 3.0 (2.6-3.5) | <.001 | 3.5 (3.1-4.0) | 3.2 (2.8-3.5) | .012 |
| Bilirubin, mg/dL | 0.4 (0.3-0.7) | 0.6 (0.4-0.9) | .002 | 0.6 (0.4-1.0) | 0.6 (0.5-1.2) | .763 |
| LDH, U/L | 312 (204-377) | 752 (457-1679) | <.001 | 833 (575-1359) | 2130 (1296-3603) | <.001 |
| ISTH-DIC score, median (IQR)* | 4 (3-4) | 6 (5-6) | <.001 | 3 (2-4) | 6 (5-7) | <.001 |
| Thrombosis | .002 | .052 | ||||
| None | 264 (89) | 30 (71) | 110 (92) | 19 (79) | ||
| Catheter-associated | 23 (8) | 6 (14) | 6 (5) | 2 (8) | ||
| Noncatheter-associated | 10 (3) | 6 (14) | 3 (3) | 3 (13) | ||
Calculated for patients with available platelet count, PT-INR, fibrinogen, and D-dimer.